UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2004

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From to

Commission File Number 000-49871

HEALTHETECH, INC.

(Exact name of registrant as specified in its charter)


Delaware		77-0478611
(State or other jurisdiction of incorporation or organization)		(I.R.S. employer identification no.)

523 Park Point Drive, 3rd Floor, Golden, Colorado		80401
(Address of principal executive office)		(Zip code)

Registrant’s telephone number, including area code: (303) 526-5085

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of August 6, 2004, the number of shares outstanding of the registrant’s common stock, par value $0.001 per share, 7,086,215.

INDEX


		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Unaudited Financial Statements	1
	Unaudited Balance Sheets	1
	Unaudited Statements of Operations	2
	Unaudited Statements of Cash Flows	3
	Notes to Unaudited Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	15
Item 4.	Controls and Procedures	15

PART II.	OTHER INFORMATION	15

Item 1.	Legal Proceedings	15
Item 2.	Changes in Securities and Use of Proceeds	15
Item 3.	Defaults Upon Senior Securities	16
Item 4.	Submission of Matters to a Vote of Security Holders	16
Item 5.	Other Information	16
Item 6.	Exhibits and Reports on Form 8-K	17

SIGNATURES		18
EXHIBIT INDEX		19

PART I. FINANCIAL INFORMATION

ITEM 1. Unaudited Financial Statements

HEALTHETECH, INC.

Balance Sheets


	December 31, 2003			June 30, 2004
				(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	17,003,224		12,762,288
Receivables, net of allowance of $307,000 and $307,000 respectively		620,428		555,839
Inventory		1,908,233		1,708,272
Prepaid expenses		676,360		305,681
Other current assets		17,979		54,560

Total current assets		20,226,224		15,386,640
Property and equipment, net		1,843,841		1,332,355
Deposits		266,398		265,313
Intangible assets, net of accumulated amortization of $2,796,970 and $2,895,988 in 2003 and 2004, respectively		1,555,742		1,498,633

TOTAL ASSETS	$	23,892,205		18,482,941

LIABILITIES & STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	567,479		326,875
Accrued liabilities		1,052,133		618,157
Deferred revenue		71,657		65,183

Total current liabilities		1,691,269		1,010,215
Other liabilities		171,640		93,250

Total liabilities		1,862,909		1,103,465
Stockholders’ equity:
Common stock, $0.001 par value, 100,000,000 shares authorized; 7,041,954 and 7,086,215 shares issued and outstanding in 2003 and 2004, respectively		7,042		7,086
Deferred stock-based charges		(1,817,371	)	(1,676,731	)
Additional paid-in capital		114,764,010		115,552,559
Accumulated deficit		(90,924,385	)	(96,503,438	)

Total stockholders’ equity		22,029,296		17,379,476

Commitments and contingencies
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY	$	23,892,205		18,482,941

The accompanying notes are an integral part of these unaudited financial statements.

HEALTHETECH, INC.

Statements of Operations

Unaudited


	Three Months Ended June 30,						Six Months Ended June 30,
	2003			2004			2003			2004
Revenue:
Product and measurement sales	$	675,235		$	791,079		$	1,603,353		$	1,403,042
Software and other		533,185			249,676			1,223,123			376,960

Total revenue		1,208,420			1,040,755			2,826,476			1,780,002

Cost of revenue:
Product and measurement sales		677,370			669,915			1,549,084			1,132,116
Software and other		459,895			132,433			733,415			307,536
Stock-based charges		2,631			7,257			51,146			25,037

Total cost of revenue		1,139,896			809,605			2,333,645			1,464,689

Gross profit		68,524			231,150			492,830			315,314
Operating expenses:
Research and development, excluding $101,295, $112,668, $680,740, and $295,492 of stock-based charges for the three months ended June 30, 2003 and 2004 and the six months ended June 30, 2003 and 2004, respectively		1,681,133			718,297			4,115,953			1,503,829
Selling, general and administrative, excluding $390,109, $202,487 $1,279,010, and $520,320 of stock-based charges for the three months ended June 30, 2003 and 2004 and the six months ended June 30, 2003 and 2004, respectively		2,843,581			1,689,695			10,333,790			3,277,586
Restructuring charges and asset impairment		2,114,026			105,102			2,114,026			377,159
Stock-based charges		491,404			315,155			1,959,750			815,812

Total operating expenses		7,130,144			2,828,248			18,523,520			5,974,386

Loss from operations		(7,061,620	)		(2,597,099	)		(18,030,690	)		(5,659,073	)
Interest income		51,115			36,698			124,169			80,842
Interest expense		(1,575	)		(120	)		(3,466	)		(822	)

Net loss	$	(7,012,080	)	$	(2,560,520	)	$	(17,909,986	)	$	(5,579,053	)

Basic and diluted loss per common share:	$	(1.79	)	$	(.36	)	$	(4.57	)	$	(.79	)

Basic and diluted weighted average number of shares outstanding		3,923,058			7,082,744			3,920,341			7,073,066

The accompanying notes are an integral part of these unaudited financial statements.

HEALTHETECH, INC.

Statements of Cash Flows

Unaudited


	Six months ended
	June 30, 2003			June 30, 2004
Cash flows from operating activities:
Net loss	$	(17,909,986	)	$	(5,579,053	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,097,325			672,922
Intangible asset impairment		1,584,600			—
Inventory reserves and write-offs		294,072			846
Loss on disposal of property and equipment		—			73,545
Stock-based charges		2,010,897			840,849
Provision for doubtful accounts		65,000			—
Change in assets and liabilities:
Receivables		2,329,027			64,589
Inventory		(139,105	)		199,115
Prepaid expenses and other current assets		2,724,198			334,098
Deposits		1,050			1,085
Accounts payable		(1,337,676	)		(240,604	)
Accrued and other liabilities		(39,236	)		(512,366	)
Deferred revenue		(319,693	)		(6,474	)

Net cash used in operating activities		(9,639,527	)		(4,151,447	)

Cash flows from investing activities:
Purchase of property and equipment		(307,019	)		(135,962	)
Proceeds from the sale of marketable securities		3,836,711			—
Purchase of intangible assets		(166,225	)		(41,909	)
Net change in restricted cash		(252	)		—

Net cash provided by (used in) investing activities		3,363,215			(177,872	)

Cash flows from financing activities:
Payments on note payable to related party		(10,000	)		—
Common stock issuance costs		—			(22,865	)
Proceeds from common stock option exercises		106,135			111,248

Net cash provided by financing activities		96,135			88,383

Net decrease in cash and cash equivalents		(6,180,177	)		(4,240,936	)
Cash and cash equivalents, beginning of period		16,878,263			17,003,224

Cash and cash equivalents, end of period	$	10,698,086		$	12,762,288

The accompanying notes are an integral part of these unaudited financial statements.

HEALTHETECH, INC.

UNAUDITED NOTES TO FINANCIAL STATEMENTS

(1) Business and Basis of Financial Statement Presentation

HealtheTech, Inc. (the Company or HealtheTech) was incorporated in February 1998 under the laws of the State of Delaware. The Company operates in one segment and develops and markets health solutions designed to give consumers simple, informative ways to improve and maintain health and wellness.

The accompanying financial statements as of June 30, 2004 and for the three months and six months ended June 30, 2003 and 2004 are unaudited and have been prepared in accordance with generally accepted accounting principles on a basis consistent with the December 31, 2003 audited financial statements and include normal recurring adjustments which are, in the opinion of management, necessary for a fair statement of the results of these periods. These statements should be read in conjunction with our financial statements and notes thereto included in our Form 10-K (Commission File No. 000-49871), filed on March 29, 2004. Operating results for the three months and six months ended June 30, 2004 are not necessarily indicative of the results that may be expected for the full year.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

The Company’s financial statements are based on several significant estimates, including the reserve for warranty obligations and product returns, provision for excess and obsolete inventory, provision for doubtful accounts and the estimated useful lives of long-lived assets, as well as the recoverability of the investment in long-lived assets.

(2) Significant Accounting Policies

(a) Cash and Cash Equivalents and Restricted Cash

All highly liquid investments purchased with original maturities of three months or less are considered to be cash equivalents.

(b) Reclassifications

Certain reclassifications have been made to prior period financial statements to conform to the 2004 presentation.

(c) Inventory

Inventory is stated at the lower of cost or market, using the first-in, first-out method and consists of purchased items or finished goods that were manufactured internally or for the Company by contract manufacturers. Our strategy utilizes both in-house and outsourced manufacturing, warehousing and shipping of our health monitoring devices, disposables and software to benefit from the resources of our contract manufacturers and fulfillment vendor where appropriate, in order to minimize the overall costs of our products. We rely on contractors for the manufacture, warehousing and shipping of the component parts for our devices.

(d) Intangible Assets

Intangible assets consist of purchased patents and legal fees to obtain patents and are recorded at cost. Amortization of intangible assets is calculated using the straight-line method over the estimated useful lives, generally five to ten years. Amortization expense was $132,244 and $50,074 for the three months ending June 30, 2003 and 2004, respectively and $276,490 and $99,018 for the six months ending June 30, 2003 and 2004, respectively. The Company periodically evaluates the recoverability of intangible assets and takes into account events and circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.

(e) Accrued liabilities

Accrued liabilities consist of the following:


	December 31, 2003		June 30, 2004
			(unaudited)
Customer deposit	$	123,842	$	13,179
Compensation		413,301		215,800
Consulting and professional services		113,684		25,550
Lease costs		194,953		162,973
Product royalties		192,076		195,103
Other		14,278		5,552

Total	$	1,052,133	$	618,157

(f) Deferred Revenue

Deferred revenue primarily consists of payments received upon sale of our BalanceLog Pro software product which is recognized ratably over the contract period.

(g) Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments, including, cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value due to their short-term nature.

(h) Research and Development Costs and Software Development Costs

Research and development costs are expensed as incurred and consist of salaries and other direct costs. SFAS No. 86, Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise Marketed, (SFAS No. 86) requires the capitalization of certain software development costs once technological feasibility is established. The Company’s software is deemed to be technologically feasible at the point a working model of the software product is developed. Through June 30, 2004, the period between achieving technological feasibility and general availability of such software has been short. Consequently, software development costs qualifying for capitalization have been insignificant.

(i) Revenue

The Company generates revenue from the sale of its products, measurements, software and licensing arrangements. Revenue from the sale of products is recognized when evidence of an arrangement exists, ownership transfers to the customer or distributor, the price is fixed and collectibility is probable. Revenue from the sale of measurements under the new pay per measurement sales model is recognized using the same criteria as product revenue. The software component of the Company’s products is considered incidental under Statement of Position (SOP) 97-2, Software Revenue Recognition.

Software fees are comprised of sales of prepackaged software that can be sold independently or in conjunction with product sales. Software fees are recognized according to the criteria of SOP 97-2, as amended. Revenue is recognized upon execution of a license agreement or signed written contract with fixed or determinable fees, shipment or electronic delivery of the product, and when collection of the receivable is probable. Software sales are to consumers who install the software themselves and pay via credit card prior to shipment.

Service revenue, including training and consulting services, is recognized as services are performed. Licensing fees are recognized ratably over the contract term.

Cost of product revenue consists primarily of purchases of products from contract manufacturers, warranty reserves, royalty payments, obsolescence reserves and costs of personnel directly related to managing the supply chain and related overhead. Cost of software revenue primarily consists of purchases of product. Additionally, costs of shipping are included in software and other costs of revenue.

The Company provides a 30 day right of return on software sales and a limited warranty on its software products for 90 days from the date of purchase. However, as returns and warranty claims have been insignificant, no reserve has been established.

In general, the Company does not provide price protection or a right of return on health monitoring devices. The Company provides a limited warranty on its devices for periods of 12 to 18 months.

(j) Stock-Based Charges

Through December 31, 2002, the Company accounted for its stock option plans in accordance with the provisions of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. Generally, compensation expense was recorded for options issued to employees and directors on the date of grant only if the current estimated fair value of the underlying common stock exceeded the exercise price of the option using the intrinsic value method. In the fourth quarter of 2003, retroactive to January 1, 2003, the Company adopted the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock-Based Compensation (FASB 123) prospectively to all employee awards granted, modified, or settled after January 1, 2003. The adoption of FASB 123 was done in accordance with FASB 148.

The Company has four stock-based employee compensation plans and presently utilizes only two of such plans to make current stock option grants. The following table illustrates the effect on net loss if the Company had applied the fair value based measurement and recognition provisions of SFAS No. 123 to stock-based employee compensation for the three months and six months ended June 30, 2003 and 2004. Stock-based employee compensation costs exclude charges recognized for the issuance of warrants.


	Three months ended June 30,						Six months ended June 30,
	2003			2004			2003			2004
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
Net loss, as reported	$	(7,012,080	)	$	(2,560,520	)	$	(17,909,986	)	$	(5,579,053	)
Stock-based employee compensation costs, included in net loss		254,840			322,411			1,456,378			840,849
Stock-based employee compensation cost, if fair value based method used		(847,735	)		(353,311	)		(2,623,720	)		(1,419,145	)

Pro forma net loss	$	(7,604,975	)	$	(2,591,420	)	$	(19,077,328	)	$	(6,157,349	)

Net loss per share, basic and diluted, as reported	$	(1.79	)	$	(0.36	)	$	(4.57	)	$	(0.79	)
Net loss per share, basic and diluted, pro forma	$	(1.94	)	$	(0.37	)	$	(4.87	)	$	(0.87	)

The Company accounts for non-employee stock based awards in accordance with SFAS No. 123 and related interpretations. Stock options are valued using the Black-Scholes option-pricing model. Prior to the Company’s initial public offering in July 2002, the fair value of equity instruments was determined by the Company’s Board of Directors. Subsequent to July 2002, the fair value is based on the closing price of the Company’s stock on the Nasdaq National Market.

(k) Income Taxes

The Company uses the asset and liability method of accounting for income taxes as prescribed by SFAS No. 109, Accounting for Income Taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The resulting deferred tax assets and liabilities are adjusted to reflect changes in tax laws or rates in the period of enactment.

(l) Advertising Costs

Advertising costs are expensed when media placements occur. Advertising expense was $0 and $0 for the three months ended June 30, 2003 and 2004, respectively and $3,332,100 and $0 for the six months ended June 30, 2003 and 2004, respectively.

(m) Loss Per Share

Loss per share is presented in accordance with the provisions of SFAS No. 128, Earnings Per Share, (SFAS No. 128). Under SFAS No. 128, basic loss per share (EPS) excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock. Basic and diluted EPS are the same for all periods, as all potential common stock instruments, consisting of common stock options and warrants and convertible preferred stock, are anti-dilutive due to the net losses for each period.

The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations:


	Three months ended June 30,						Six months ended June 30,
	2003			2004			2003			2004
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
Numerator:
Net loss	$	(7,012,080	)	$	(2,560,520	)	$	(17,909,986	)	$	(5,579,053	)
Denominator:
Historical common shares outstanding for basic and diluted loss per share at beginning of the period		3,923,058			7,082,744			3,912,536			7,041,954
Weighted average number of common equivalent shares issued during the period		—			—			7,805			31,112

Denominator for basic and diluted loss per share—weighted average shares		3,923,058			7,082,744			3,920,341			7,073,066

Basic and diluted net loss per share	$	(1.79	)		(0.36	)	$	(4.57	)		(0.79	)

Potential common stock equivalents, consisting of options and warrants, for the six months ended June 30, 2003 and 2004 were 1,889,586 and 2,454,649, respectively, and were excluded from the diluted loss per share calculation because their effect would be anti-dilutive.

In December 2003, the Company effectuated a 1-for-5 reverse split of its outstanding common stock after the close of the markets on December 31, 2003. The reverse stock split was approved by the Company’s stockholders at a special meeting held on December 19, 2003. All shares and per share data have been restated to reflect this change.

(2) Restructuring Charge

During the second quarter of 2003, the Company decided to refocus its business on the medical markets and commercial weight loss, corporate wellness, and fitness markets and the products that support those markets. As a result of this refocus, the Company evaluated its operating expense levels and determined to restructure the business, resulting in a Company-wide cost reduction program achieved through a downsizing of the employee workforce, a significant reduction in use of contractors and outside service firms, and Company-wide temporary salary reductions. Restructuring charges include severance arrangements, early termination fees and legal costs. The cost reduction program was consummated in two steps with restructuring charges of approximately $529,000 and $249,000 in the second and fourth quarters of 2003, respectively. Additional costs of $272,057 and $105,102 were incurred in the first and second quarters of 2004, respectively, relating to the 2003 restructuring program, which included lease termination costs and severance arrangements. As of June 30, 2004, a balance of $60,066 remains in accrued liabilities representing salary expense to be paid by December 31, 2004.


	June 30, 2004
	(unaudited)
Accrued liability at December 31, 2003	$	225,703
Restructuring charge recorded		377,159
Cash paid by June 30, 2004		(542,796	)

Liability remaining at June 30, 2004	$	60,066

(3) Property and Equipment

Property and equipment consist of the following:


	December 31, 2003			June 30, 2004		Estimated useful life
	(unaudited)
Furniture and fixtures	$	423,461		378,154		60 months
Computer equipment		1,250,829		1,269,563		36 months
Development tools		653,283		686,326		18 months
Leasehold improvements		796,135		688,245		60 months
Purchased software		974,159		986,965		36 months
Laboratory Equipment		205,263		205,263		36 months
Capitalized website and software		769,156		769,156		24 months
Capital projects in process		129,076		139,890

		5,201,362		5,123,563
Less accumulated depreciation and amortization		(3,357,521	)	(3,791,208	)

Total property and equipment	$	1,843,841		1,332,355

(4) Line of Credit

The Company has a credit facility with a $2.5 million line of credit which requires us to keep a minimum of $3.9 million in cash on deposit at the bank and meet minimum tangible net worth and liquidity thresholds. As of June 30, 2004, the only use of the credit facility was the provision of a $1.2 million letter of credit supporting the lease of its corporate headquarters in Golden, Colorado. Cash advances under the credit facility are available pursuant to a borrowing-base formula and subject to the maintenance of certain financial covenants and other terms and conditions. The amount of available credit under the line approximates $1.3 million at June 30, 2004.

(5) Stockholders’ Equity

(a) Employee Stock Purchase Plan

The Company has an employee stock purchase plan for all eligible employees. Under the plan, shares of the Company’s common stock may be purchased at six-month intervals at 85% of the lower of the fair value on the first or the last day of each six-month period. Employees may purchase shares having a value not exceeding 15% of their gross compensation during an offering period. For the six-month offering period ended February 17, 2004, employees purchased 1,500 shares of common stock at a price of $2.85 per share.

(b) Stock Options

On March 29, 2004, the Company re-priced existing options to purchase 327,047 shares of common stock at an exercise price of $1.84 per share. These options retain their prior vesting schedule and expiration date. Additionally, the Company cancelled and reissued options to purchase 60,336 shares of common stock. These options have an exercise price of $1.84 per share and vest over four years and expire in March 2014. In addition, the Company granted 500,000 options to purchase common stock at an exercise price of $1.84 per share and vest over four years and expire in March 2014. The fair value for these option grants and modifications totaled approximately $1.0 million and is being expensed over the vesting period of the options. The fair value was determined using the Black-Scholes Option Pricing model with the following assumptions: volatility 105%, no dividend yield, risk free interest rates of 0.83% to 3.25% and expected lives of 0 to 4 years.

The following table summarizes stock option activity and balances for the periods ended June 30, 2003 and 2004:


	2003 Number of options		2003 Weighted- average exercise price	2004 Number of options		2004 Weighted- average exercise price
Beginning balance, January 1	901,636		$22.20	1,343,607		$14.41
Granted	353,136		11.65	965,833		1.90
Exercised	(85	)	13.15	(40,790	)	2.50
Forfeited	(28,264	)	29.15	(523,867	)	19.99

Balance at March 31 (unaudited)	1,226,423		$19.00	1,744,783		$ 6.09
Granted	403,000		3.30	188,410		2.19
Exercised	—		—	—		—
Forfeited	(106,895	)	24.45	(94,904	)	20.65

Balance at June 30 (unaudited)	1,522,528		$14.65	1,838,289		$ 4.94

The following table summarizes information about stock options outstanding at June 30, 2004:


Range of exercise prices	Number outstanding	Weighted average remaining contractual life	Weighted Average Exercise price	Number Exercisable as of June 30, 2004	Weighted Average Exercise price
$1.84	902,167	9.19	$ 1.84	110,977	$ 1.84
$2.00 – $2.50	476,150	6.18	2.38	287,240	2.50
$3.50 – $8.40	209,433	1.87	6.65	202,371	6.69
$9.38 – $21.00	174,946	3.50	12.67	167,941	12.66
$28.60—$37.50	75,593	7.38	35.34	65,739	35.02

	1,838,289	6.96	$ 4.94	834,268	$ 8.04

The following table includes grants of options for common stock whose exercise price was less than the fair value, for financial reporting purposes, of the underlying common stock at the date of grant, equal to the fair value at the date of grant or greater than the fair value at the date of grant. The weighted average fair value was determined using the Black-Scholes option-pricing model.


	Three months ended June 30,				Six months ended June 30,
	2003		2004		2003		2004
Exercise Price:
Less than fair value—Number of options		371,800		—		371,800		—
Weighted average exercise price	$	2.50		—	$	2.50		—
Weighted average fair value	$	2.45		—	$	2.45		—
Equal to fair value—Number of options		23,200		188,410		353,336		1,154,243
Weighted average exercise price	$	4.30	$	2.19	$	10.15	$	1.95
Weighted average fair value	$	2.10	$	1.50	$	6.45	$	1.34
Greater than fair value—Number of options		8,000		—		31,000		—
Weighted average exercise price	$	37.50		—	$	37.50		—
Weighted average fair value	$	5.35		—	$	3.75		—

The following table includes weighted average assumptions using the Black-Scholes option pricing model for determining the per share weighted average fair value of stock options granted:


	Three months ended June 30,						Six months ended June 30,
	2003			2004			2003			2004
Per share weighted average fair value	$	2.49		$	1.50		$	4.37		$	1.34
Dividends		—			—			—			—
Volatility		109	%		100	%		100	%		100%-105	%
Risk-free interest rate		1.08	%		3.16	%		1.72	%		1.04%-3.16	%
Expected life		1.21 years			4 years			2.49 years			0-4 years

(6) Significant Customers

Revenue earned from significant customers is as follows:


	Three months ended June 30,				Six months ended June 30,
	2003		2004		2003		2004
Customer A	—		38	%	—		24	%
Customer B	—		5	%	18	%	14	%
Customer C	49	%	—		27	%	—
Customer D	5	%	—		10	%	—

At June 30, 2003 and 2004, receivables from these customers represented 78% and 75% of total receivables, respectively.

(7) Related Party Transactions

None.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of HealtheTech, Inc.’s (referred to herein as the Company, we, us or our) financial condition and results of operations should be read in conjunction with the financial statements and notes thereto included in Item 1 of Part 1 of this quarterly report and the audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2003 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission. The following Management’s Discussion and Analysis of Financial Condition and Results of Operations, as well as information contained elsewhere in this report, contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” “plan,” “could,” “should,” and “continue,” or similar words. Actual results could differ materially from those anticipated in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those mentioned in the discussion below, the summary “Risk Factors” contained herein and those described in the “Risk Factors” discussion of our Annual Report on Form 10-K for the year ended December 31, 2003. As a result, you should not place undue reliance on these forward-looking statements. We do not intend to update or revise these forward-looking statements to reflect future events or developments.

Overview

We were incorporated in Delaware in February 1998. We design, develop and market technologically advanced and proprietary handheld medical devices and software for the measurement of resting metabolic rate and the monitoring of nutrition.

We have incurred losses since commencing operations and, as of June 30, 2004, we had an accumulated deficit of $96.5 million. Our net loss was $7.0 million and $2.6 million for the three months ended June 30, 2003 and 2004, respectively, and $18.0 million and $5.6 million for the six months ended June 30, 2003 and 2004, respectively. We have not achieved profitability on a quarterly or annual basis. We intend to continue to develop and market our proprietary products and services and increase our focused sales efforts.

We derive revenue from the sale of our health monitoring devices, single-use disposables, software products and license fees. We anticipate that our revenue will be generated primarily through direct sales and sales by our distributors and resellers into the medical therapy, weight management and fitness markets. Our sales strategy is to establish relationships with distributors or resellers in each channel that already possess the sales, marketing and distribution capabilities needed to reach our end users.

Beginning in 2004, we converted our future sales efforts to a “measurement” business model in which customers receive MedGem and BodyGem devices from us, either directly or through commissioned sales agents. These devices are “preloaded” with the ability to perform a specific number of metabolic measurements and can be reloaded with additional measurements. Customers also receive a corresponding number of disposable mouthpieces at no additional charge. The principal advantage of this model to our customers is that it lowers the initial acquisition cost of deploying the device in the customer’s business. As a result, we expect the model to accelerate the adoption, deployment and utilization rate of our devices, increasing our installed base of devices and, ultimately, positively impacting revenue and profitability. In the first year of deployment of this model, however, our revenue is likely to be lower than it would be under the traditional sales model, because the expected selling price of a set number of measurements is expected to be lower than the traditional selling price of a measurement device and quantity of disposable mouthpieces. Although this model has only been in place since January 2004, we expect that this system of selling measurements, rather than devices and disposables, will be the dominant form of business in 2004 and beyond.

In 2003 we refocused our business model on the medical, commercial weight loss and fitness markets and the products that support those markets. As a result of this market focus, we in turn have completed the first two quarters of 2004 on plan for lowering operating expenses, including the closure of our Los Gatos, California research and development facility. We incurred a $200,977 expenditure in January 2004 as a termination fee for this facility lease. Despite the progress we made in reducing expenses, we will need to generate substantially higher revenue than that generated in past quarters and/or further reduce expenses in order to achieve and sustain profitability.

We are continuing to build and support our growing distribution network to represent our products in key markets throughout the United States and the European, Middle Eastern and African fitness markets. In addition, we have established key relationships in the fitness market and have pilot programs underway in a number of other commercial fitness, weight loss and medical settings.

In December 2003, Malacca International Corporation, a subsidiary of Microlife Corporation filed suit against us alleging breach of contract. In February 2004, we filed our answer denying the material allegations in the complaint and asserted counterclaims against both Malacca and Microlife for breach of contract and unjust enrichment. See “Part II, Item 1: Legal Proceedings” for a further description of the dispute. While management currently believes that resolving this matter will not have a material adverse impact on the Company’s financial position or its results of operations, litigation is subject to inherent uncertainties and management’s view of these matters may change in the future. Were an unfavorable final outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position and the results of operations.

Results of Operations

Three Months and Six Months Ended June 30, 2004 and 2003

Revenue. Revenue decreased $0.2 million, or 14%, to $1.0 million in the quarter ended June 30, 2004 from $1.2 million in the comparable quarter in 2003. Product and Measurement revenue increased $0.1 million, or 17%, to $0.8 million for the three months ended June 30, 2004 from $0.7 million in the comparable period in 2003. Software and other revenue decreased $0.3 million, or 53%, to $0.2 million in the second quarter of 2004 from $0.5 million in the comparable quarter of 2003. This decrease is due largely to our exit from the mass-market retail channel during the second quarter of 2003. Software revenue was enhanced during the second quarter of 2004 by a $124,000 revenue recognition for revenue that had been deferred from a previous period.

Revenue decreased $1.0 million, or 37%, to $1.8 million for the six months ended June 30, 2004 from $2.8 million in the comparable period in 2003. Product and Measurement revenue decreased $0.2 million, or 12%, to $1.4 million for the six months ended June 30, 2004, from $1.6 million in the comparable period in 2003. The decrease reflects our strategy to move away from agreements that couple minimum purchase agreements with exclusivity, as we believe this will promote more competitiveness among our distributors in the market and also cause our reported revenue to better reflect the deployment and usage of our products. Under the new strategy, the shipment from our manufacturing facility is more closely aligned with the end user’s consumption of the unit’s measurements. Software and Other revenue decreased $0.8 million, or 69%, to $0.4 million for the six months ended June 30, 2004, from $1.2 million in the comparable period in 2003. Certain reclassifications have been made for the first quarter between Software and Other revenue with Product and Measurement revenue to conform to the current period’s presentation.

Revenue from customers outside the United States accounted for 4% and 48% of total revenue for the three months ended June 30, 2004 and 2003 respectively and 10% and 27% of total revenue for the six months ended June 30, 2004 and 2003, respectively.

Cost of Revenue. Total cost of revenue decreased to 78% of sales in the second quarter of 2004 from 94% of sales in the second quarter of 2003. Total cost of revenue for the six months ended June 30, 2004 decreased to 82% of sales from 83% of sales in the prior year period. Total cost of revenue improved during the second quarter 2004 due the $124,000 deferred revenue recognition that resulted in a 100% margin.

Research and Development. Research and development expenses decreased $1.0 million, or 57%, to $0.7 million in the quarter ended June 30, 2004 from $1.7 million in the comparable quarter in 2003.

Research and Development expense decreased $2.6 million, or 63%, to $1.5 million for the six months ended June 30, 2004 from $4.1 million in the comparable period of the prior year. The Company has reduced research and development headcount by 38% resulting from the cost reduction measures undertaken in the second and fourth quarters of 2003. In addition, we have reduced our use of outside service firms and contractors. We have focused our research and development efforts on a few key projects, which are now being handled with internal resources, and clinical validation studies conducted by outside providers. We believe that a continued commitment to research and development is essential in order to provide enhancements to and validation of existing products.

Selling, General and Administrative. Selling, general and administrative expenses decreased $1.1 million, or 41%, to $1.7 million in the quarter ended June 30, 2004 from $2.8 million in the comparable quarter of 2003.

Selling, general and administrative expense decreased $7.0 million, or 68%, to $3.3 million for the six months ended June 30, 2004, from $10.3 million in the comparable period of the prior year. We significantly reduced marketing spending in the latter half of 2003. In late 2002, we were preparing for the launch of our BalanceLog software into the retail channel by hiring marketing firms to conduct consumer and medical studies, packaging firms for product redesign, and a marketing agency for promotion services. Although this activity was curtailed in early 2003 with our shift in distribution strategy away from retail, significant expense was still incurred in the first quarter of 2003. Subsequent to the first quarter of 2003, our marketing expenditures have been modest. Other reasons for the decrease in selling, general and administrative expenses include a 43% reduction in headcount, as a result of our second and fourth quarter 2003 cost reduction efforts. As a further cost efficiency, we are now using internal resources for most formerly contracted functions, such as web hosting, customer service, and investor and public relations.

Stock-based Charges. Stock-based charges decreased $0.2 million, or 36%, for the second quarter of 2004 to $0.3 million from $0.5 million in the comparable quarter of the prior year. Stock-based charges decreased $1.2 million, or 58%, for the six months ended June 30, 2004, to $0.8 million from $2.0 million in the comparable period of the prior year. On March 29, 2004, the Company re-priced existing options to purchase 327,047 shares of common stock at an exercise price of $1.84 per share. These options retain their prior vesting schedule and expiration date. Additionally, the Company cancelled and reissued 60,336 options to purchase common stock. These options have an exercise price of $1.84 per share, vest over four years and have a life of ten years. In addition, the Company granted 500,000 options to purchase common stock at an exercise price of $1.84 per share and vest over four years and expire in March 2014. The fair value for these option grants and modifications totaled approximately $1.0 million and are being amortized to expense over the vesting period of the options.

Restructuring Charges and Asset Impairment. During the second and fourth quarters of 2003, we implemented a company-wide cost reduction program. This was achieved through a downsizing of our employee workforce, a significant reduction in our use of contractors and outside service firms, and company-wide temporary salary reductions. Associated with this effort, we incurred approximately $272,000 and $105,000 of severance charges and lease termination costs for the first and second quarters of 2004, respectively. Additionally, through the end of 2003, we leased a facility in Los Gatos, California for research and development activities under a lease that expires in May 2005 and provides for a payment of $26,797 per month. In January 2004, we provided a lump-sum payment of $200,977 in exchange for an early termination of any further obligations under the lease.

Liquidity and Capital Resources

Cash and cash equivalents totaled $12.8 million at June 30, 2004. Cash used in operating activities was $4.2 million in the six months ended June 30, 2004 compared to $9.6 million in the comparable period of 2003. The decrease in usage reflects the improvement in our cost structure previously discussed in the Results of Operations section of this document.

Cash used in investing activities was $0.2 million in the six months ended June 30, 2004, a change from $3.4 million provided in the comparable period of the prior year, primarily due to the sale of marketable equity securities during the first quarter of 2003.

Cash flows from financing activities were $0.1 million in the six months ended June 30, 2004, essentially the same as the $0.1 million recorded in the comparable period of the prior year. Net cash from financing activities primarily reflects proceeds from the sale of equity securities from our employee stock purchase plan and exercise of stock options.

We have no debt. Stockholders’ equity at June 30, 2004 was $17.4 million. We expect to continue to modestly invest in sales and marketing programs and research and development. We do not expect significant additions to property and equipment for the remainder of 2004.

The following table sets forth information concerning our material contractual obligations as of June 30, 2004:


Material Contractual Obligations	Total			Due in next 6 months			Due 2005			Due 2006		Due 2007 or after
Operating Lease Obligations, Gross	$	2,269,153		$	380,204		$	640,251		$	527,846	$	720,851
Sublease Agreement	$	(96,000	)	$	(48,000	)	$	(48,000	)		—		—

Operating Lease Obligations, Net	$	2,173,153		$	332,204		$	592,251		$	527,846	$	720,851

Critical Accounting Policies and Estimates

We have disclosed in Note 2 to our financial statements those accounting policies that we consider to be significant in determining our results of operations and our financial position.

The preparation of financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We evaluate our estimates, including those related to bad debts, inventories and warranty obligations, on an ongoing basis. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the periods presented. The actual results may differ from these estimates under different assumptions or conditions.

The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

Revenue recognition

We derive our revenue primarily from the sale of our health monitoring devices, the recurring sale of our single-use disposables and our companion software. Beginning in 2004 with the conversion of our future sales efforts to a measurement model, we recognize the revenue from pre-loaded devices containing measurements of 20 and 100 at the time the device is delivered. Our software revenue is recognized in accordance with Statement of Position 97-2, as amended by Statement of Position 98-9. We license our software products on a perpetual basis. We recognize revenue from the sale of our health monitoring devices and single-use disposables upon ownership transfer to the customer and when it is determined that a continuing service obligation no longer exists. We recognize revenue from the sale of our software, when persuasive evidence of an arrangement exists, the product is delivered, the price is fixed or determinable and collectibility is probable. For sales of our software over the Internet, we use a credit card authorization as evidence of an arrangement. Sales through our distributors are evidenced by a master agreement governing the relationship together with binding purchase orders on a transaction-by-transaction basis. Delivery generally occurs when the product is delivered to a common carrier. Service revenue, including training, is recognized as services are performed. We offer customers the right to return software products that do not function properly within a limited time after delivery, typically 90 days. We provide limited warranties on our health monitoring devices for a period of 12 months from the date of purchase and on our software products for 90 days from date of purchase, with certain limited exceptions.

Receivables are recorded net of allowance for doubtful accounts. We regularly review the adequacy of our accounts receivable allowance after considering the accounts receivable aging, the ages of each invoice, each customer’s expected ability to pay and our collection history with each customer. We review any invoice greater than 90 days past due to determine if an allowance is appropriate based on the risk category using the factors discussed above. The allowance for doubtful accounts represents our best estimate, but changes in circumstances relating to accounts receivable may result in additional allowances or recoveries in the near future.

Stock-based charges

At June 30, 2004, we had four stock-based employee compensation plans. Prior to 2003, we accounted for those plans under the recognition and measurement provisions of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations. Prior to 2003, stock-based employee compensation cost was reflected in net loss to the extent that options granted under the plan had an exercise price less than the fair value of the underlying common stock on the date of grant. Effective January 1,

2003, we adopted the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock-Based Compensation, prospectively to all awards granted, modified, or settled after January 1, 2003 under the employee compensation plans. The 2003 impact of the FASB 123 adoption, $1.8 million, was reported entirely in the fourth quarter of 2003. Awards under our employee compensation plans vest over periods ranging from zero to four years. Accordingly, the cost related to stock-based employee compensation included in the determination of net income (loss) for 2002 and prior years is less than that which would have been recognized if the fair value based method had been applied to all awards since the original effective date of Statement 123.

Valuation allowances

Management makes estimates of potential future product returns and product warranties related to current period product revenue, based on historical returns, current economic trends and changes in customer demand and acceptance of our products when evaluating the adequacy of the sales returns and other allowances. Significant management judgments and estimates must be made and used in connection with establishing the sales returns and other allowances in any accounting period. Significant differences may result in the amount and timing of our revenue for any period if management made different judgments or used different estimates.

Risk Factors

In addition to the other information contained in this report, we caution stockholders and potential investors that the following summary risk factors and those additional factors described in the “Risk Factors” discussion of our Annual Report on Form 10-K for the year ended December 31, 2003, in some cases have affected, and in the future could affect, our actual results of operations and could cause our actual operating results to differ materially from those expressed in any forward-looking statements made by or on our behalf. The following information is not intended to limit in any way the characterization of other statements or information under other captions or in the “Risk Factors” section of our Annual Report on Form 10-K for such purpose.

Following is a summary of the risk factors identified in our Form 10-K for the year ended December 31, 2003 that could cause our financial condition to differ from projections:

•

Our brief operating history makes it difficult to evaluate our prospects.

•

We recorded only $23.9 million in revenue from our inception through June 30, 2004, we have a large accumulated deficit, we expect future losses and we may not achieve or maintain profitability.

•

Beginning in 2004, we converted to a measurement business model from which we expect to derive substantially all of our future MedGem and BodyGem revenue. If acceptance of our new business model fails to develop as we expect or otherwise declines, we could fail to generate sufficient revenues to achieve profitability.

•

We expect our future financial results to fluctuate significantly, and failure to increase our revenue or achieve profitability may disappoint securities analysts or investors and result in a decline in our stock price.

•

We may be unable to maintain our listing on the Nasdaq National Market.

•

We are currently, and in the future could be, involved in litigation which could adversely impact our financial position.

•

We have very limited product offerings from which we expect to derive substantially all of our future revenue. If demand for our limited number of products fails to develop as we expect or otherwise declines, we could fail to generate sufficient revenue to achieve profitability.

•

We currently rely on a limited number of distributors and resellers for the sale of the MedGem and BodyGem devices into our target markets. If these distributors and resellers are not successful selling our products, or if we are unable to establish additional distributor and reseller arrangements as planned, we will not be able to achieve our sales goals and our business will be harmed.

•

Because a small number of customers are likely to account for a substantial portion of our revenue, the loss of any of these customers or the cancellation or deferment of a customer’s order could cause our revenue to decline substantially and may result in a decline in our share price.

•

Our workforce reductions may have an adverse impact on our ability to recruit and retain key personnel, which could delay our ability to execute our business plan.

•

If we cannot convince healthcare professionals, wellness advisors and their patients and clients of the importance of measuring metabolism for nutrition monitoring, weight management and fitness applications and of the benefits of our products, we will not be able to increase our revenue and our operating results would suffer.

•

The commercial weight management and fitness markets are characterized by short-lived trends and we may not experience increased demand for our products, or any increase in demand may be short-lived.

•

We purchase one of our key components, an oxygen sensor, from a sole source. If this source fails to satisfy our supply requirements on a timely basis, we may lose sales and experience increased component costs and our customer relationships may be harmed.

•

Our health monitoring devices and our software products may contain unknown errors or defects, which could result in rejection of our products and damage to our reputation, as well as lost revenue, diverted development resources and increased service costs and warranty claims.

•

If we fail to maintain necessary FDA or other regulatory clearance for the marketing and sale of the MedGem devices or if we fail to obtain or maintain necessary FDA or other regulatory clearance or approvals for the marketing and sale of any other medical devices that we may develop in the future, or if clearances or approvals are delayed, we will be unable to commercially distribute and market those medical devices in the United States or abroad.

•

Modifications to the MedGem device may require a new 510(k) clearance or premarket approval or require us to cease marketing or recall the modified device until these clearances or approvals are obtained.

•

If we or our third-party manufacturers fail to comply with the FDA’s Quality System regulation with respect to the MedGem device and any other medical devices that we may produce in the future, our manufacturing operations could be delayed, and the MedGem device sales and our profitability could suffer.

•

The MedGem device and any other medical devices that we may produce in the future are subject to product recalls even after receiving regulatory clearance or approval. Product recalls would harm our reputation and result in increased costs, either of which could harm our operating results.

•

If we fail to protect our intellectual property rights, our competitors may take advantage of our ideas and compete directly against us.

•

If we infringe the patents or proprietary rights of other parties, our ability to grow our business will be severely limited.

•

We license or sublicense key technology from third parties. If necessary licenses or sublicenses of technology are terminated or become unavailable or too expensive, or if licensors or sublicensors fail to prosecute and enforce patents licensed to us, our competitive position and our product offering will suffer.

•

Our business exposes us to risks of product liability claims, and we may incur substantial expenses that exceed our insurance coverage if we are sued for product liability.

•

We may have warranty claims that exceed our reserves.

•

We face risks related to our international operations, including the need to maintain ISO certification and CE Marking approval and obtain necessary foreign regulatory clearance or approvals.

•

Failure to raise additional capital or to generate the significant capital necessary to expand our operations and invest in new products and technologies could reduce our ability to compete and to take advantage of market opportunities and could result in lower revenue.

•

The expense of using our products may not be subject to reimbursement by Medicare, Medicaid or third-party payors, such as health insurance companies. Even if a procedure including our products may be covered, any adverse changes in reimbursement procedures by Medicare, Medicaid or other third-party payors for procedures that include our products may limit our ability to market and sell the MedGem device.

•

We face competition from competitors with greater resources, and competition from personal health technology companies and fitness, nutrition and weight management software companies could increase, which may make it more difficult for us to achieve any significant market penetration.

•

Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us more difficult.

•

We have adopted a stockholder rights plan that may discourage, delay or prevent a merger or acquisition that is beneficial to our stockholders.

•

Directors, executive officers, principal stockholders and affiliated entities beneficially own approximately 56% of our capital stock and may be able to exert control over our activities.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Our interest income is sensitive to changes in the general level of interest rates in the United States, particularly since the majority of our investments are short-term in nature. Due to the nature of our short-term investments, we have concluded that we do not have material market risk exposure.

Our investment policy requires us to invest funds in excess of current operating requirements. At June 30, 2004, our cash and cash equivalents consisted primarily of short-term U.S. governmental securities with original maturities of three months or less. The recorded carrying amounts of cash and cash equivalents approximate fair value due to their short maturities.

Item 4.

Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit to the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified by the Commission’s rules and forms, and that information is accumulated and communicated to our management, including our principal executive and principal financial officers (whom we refer to in this periodic report as our Certifying Officers), as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Certifying Officers, the effectiveness of our disclosure controls and procedures as of June 30, 2004, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of June 30, 2004, our disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting that occurred during our fiscal quarter ended June 30, 2004 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

In the ordinary course of business, we may from time to time become involved in certain legal proceedings. As of the date of this quarterly report, we are a party to one legal proceeding. On December 22, 2003, Malacca International Corporation, a subsidiary of Microlife Corporation (“Microlife”), filed suit against us in the United States District Court for the District of Colorado alleging breach of contract in connection with our International Distribution Agreement dated March 19, 2002. The complaint alleges that we breached the agreement by failing to maintain Microlife’s exclusivity and failed to have product available for distribution and seeks rescission of the agreement or an injunction and monetary damages. Microlife is also seeking an injunction prohibiting us from providing product to other distributors serving the markets covered by the agreement. We believe that we have meritorious defenses and that the specified claims are without merit and intend to vigorously contest this lawsuit. On February 2, 2004, we filed our answer denying the material allegations in Malacca’s complaint and asserted counterclaims against both Malacca and Microlife for breach of contract and unjust enrichment. The lawsuit is in the discovery stage at the present time.

While management currently believes that resolving this matter will not have a material adverse impact on our financial position or results of operations, litigation is subject to inherent uncertainties and management’s view of these matters may change in the future. Were an unfavorable final outcome to occur, there exists the possibility of a material adverse impact on our financial position and the results of operations.

Item 2.

Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Submission of Matters to a Vote of Security Holders

On May 7, 2004, we held the annual meeting of stockholders of the Company for the following purposes:

1. To elect one Class II director, James Dennis, to hold office until the 2007 Annual Meeting of the Stockholders. The votes cast and withheld for such proposal were as follows:


For		Withhold Authority
4,602,334		9,746

2. To ratify the selection of KPMG LLP by the Audit Committee of the Board of Directors as independent auditors of the Company for the fiscal year ending December 31, 2004. The votes cast and withheld for such proposal were as follows:


For	Against	Abstaining
4,607,150	3,594	1,336

3. To approve certain amendments to the 2002 Stock Plan (the “Plan”) to (i) increase the base number of common stock authorized for issuance under the Plan by 100,000 from 666,667 shares to 766,667 shares; (ii) increase the base number of shares of common stock authorized for issuance under the Plan on the first day of each fiscal year beginning in 2005, in an amount equal to the lesser of (a) 500,000 shares of common stock, (b) 5% of the aggregate of (x) the outstanding shares of common stock on such date and (y) such number of shares of common stock that are issuable upon the exercise of the outstanding warrants issued to certain investors on December 23, 2003 in a private placement transaction, or (c) an amount determined by our Board of Directors; and (iii) increase the number of shares that the Company may grant in any fiscal year to any one individual under the Plan from 133,333 shares to 500,000 shares. The votes cast and withheld for such proposal were as follows:


For	Against	Abstaining	Broker Non-Vote
2,853,476	149,683	6,786	1,602,135

Based on these reporting results, each of these matters was approved by the Company’s stockholders.

Item 5.

Other Information

None.

Item 6.

Exhibits and Reports on Form 8-K

(a) Exhibits


Number		Description
31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Chief Accounting Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32		Certifications of the Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K

1. Current Report on Form 8-K furnished under Item 12 (Results of Operations and Financial Condition) on May 6, 2004.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 9, 2004


		HEALTHETECH, INC. (Registrant)

By:		/S/ JAMES W. DENNIS
		James W. Dennis Chairman and Chief Executive Officer

By:		/S/ RICK FRESIA
		Rick Fresia Vice President Finance (Principal Financial and Accounting Officer)

EXHIBIT INDEX

Exhibits


Number		Description
31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Chief Accounting Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32		Certifications of the Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

HEALTHETECH INC 10-Q